Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Income towards Parent Company: 2009-2025

Historic Income towards Parent Company for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to $17.3 million.

  • Amicus Therapeutics' Income towards Parent Company rose 357.19% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.1 million, marking a year-over-year increase of 86.57%. This contributed to the annual value of -$56.1 million for FY2024, which is 62.99% up from last year.
  • Amicus Therapeutics' Income towards Parent Company amounted to $17.3 million in Q3 2025, which was up 170.87% from -$24.4 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Income towards Parent Company registered a high of $17.3 million during Q3 2025, and its lowest value of -$85.3 million during Q1 2022.
  • Its 3-year average for Income towards Parent Company is -$21.5 million, with a median of -$21.7 million in 2025.
  • Examining YoY changes over the last 5 years, Amicus Therapeutics' Income towards Parent Company showed a top increase of 357.19% in 2025 and a maximum decrease of 55.57% in 2025.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' Income towards Parent Company stood at -$83.3 million in 2021, then surged by 32.92% to -$55.9 million in 2022, then surged by 39.42% to -$33.8 million in 2023, then soared by 143.55% to $14.7 million in 2024, then surged by 357.19% to $17.3 million in 2025.
  • Its Income towards Parent Company stands at $17.3 million for Q3 2025, versus -$24.4 million for Q2 2025 and -$21.7 million for Q1 2025.